284 related articles for article (PubMed ID: 35279714)
1. Identification of alternative splicing-derived cancer neoantigens for mRNA vaccine development.
Cheng R; Xu Z; Luo M; Wang P; Cao H; Jin X; Zhou W; Xiao L; Jiang Q
Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35279714
[TBL] [Abstract][Full Text] [Related]
2.
Zhang Z; Zhou C; Tang L; Gong Y; Wei Z; Zhang G; Wang F; Liu Q; Yu J
Aging (Albany NY); 2020 Jul; 12(14):14633-14648. PubMed ID: 32697765
[TBL] [Abstract][Full Text] [Related]
3. Neoantigens: promising targets for cancer therapy.
Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
[TBL] [Abstract][Full Text] [Related]
4. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy.
Li G; Mahajan S; Ma S; Jeffery ED; Zhang X; Bhattacharjee A; Venkatasubramanian M; Weirauch MT; Miraldi ER; Grimes HL; Sheynkman GM; Tilburgs T; Salomonis N
Sci Transl Med; 2024 Jan; 16(730):eade2886. PubMed ID: 38232136
[TBL] [Abstract][Full Text] [Related]
5. Toward in silico Identification of Tumor Neoantigens in Immunotherapy.
Zhou C; Zhu C; Liu Q
Trends Mol Med; 2019 Nov; 25(11):980-992. PubMed ID: 31494024
[TBL] [Abstract][Full Text] [Related]
6. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.
Trivedi V; Yang C; Klippel K; Yegorov O; von Roemeling C; Hoang-Minh L; Fenton G; Ogando-Rivas E; Castillo P; Moore G; Long-James K; Dyson K; Doonan B; Flores C; Mitchell DA
Genome Med; 2024 Jan; 16(1):17. PubMed ID: 38268001
[TBL] [Abstract][Full Text] [Related]
7. Tumor neoantigens: Novel strategies for application of cancer immunotherapy.
Guan H; Wu Y; Li LU; Yang Y; Qiu S; Zhao Z; Chu X; He J; Chen Z; Zhang Y; Ding H; Pan J; Pan Y
Oncol Res; 2023; 31(4):437-448. PubMed ID: 37415744
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing.
Wickland DP; McNinch C; Jessen E; Necela B; Shreeder B; Lin Y; Knutson KL; Asmann YW
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754917
[TBL] [Abstract][Full Text] [Related]
9. Sources of Cancer Neoantigens beyond Single-Nucleotide Variants.
Capietto AH; Hoshyar R; Delamarre L
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077528
[TBL] [Abstract][Full Text] [Related]
10. Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials.
Ingels J; De Cock L; Mayer RL; Devreker P; Weening K; Heyns K; Lootens N; De Smet S; Brusseel M; De Munter S; Pille M; Billiet L; Goetgeluk G; Bonte S; Jansen H; Lint SV; Leclercq G; Taghon T; Menten B; Vermaelen K; Impens F; Vandekerckhove B
Cytotherapy; 2022 Feb; 24(2):213-222. PubMed ID: 34696961
[TBL] [Abstract][Full Text] [Related]
11. Towards customized cancer vaccines: a promising filed in personalized cancer medicine.
Xu X; Zhou Z; Li H; Fan Y
Expert Rev Vaccines; 2021 May; 20(5):545-557. PubMed ID: 33769185
[TBL] [Abstract][Full Text] [Related]
12. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
13. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in mRNA cancer vaccines.
Yao R; Xie C; Xia X
Hum Vaccin Immunother; 2024 Dec; 20(1):2307187. PubMed ID: 38282471
[TBL] [Abstract][Full Text] [Related]
15. Design of Personalized Neoantigen RNA Vaccines Against Cancer Based on Next-Generation Sequencing Data.
Alburquerque-González B; López-Abellán MD; Luengo-Gil G; Montoro-García S; Conesa-Zamora P
Methods Mol Biol; 2022; 2547():165-185. PubMed ID: 36068464
[TBL] [Abstract][Full Text] [Related]
16. Identification of neoantigens derived from alternative splicing and RNA modification.
Park J; Chung YJ
Genomics Inform; 2019 Sep; 17(3):e23. PubMed ID: 31610619
[TBL] [Abstract][Full Text] [Related]
17. Development of neoantigens: from identification in cancer cells to application in cancer vaccines.
Ebrahimi N; Akbari M; Ghanaatian M; Roozbahani Moghaddam P; Adelian S; Borjian Boroujeni M; Yazdani E; Ahmadi A; Hamblin MR
Expert Rev Vaccines; 2022 Jul; 21(7):941-955. PubMed ID: 34196590
[TBL] [Abstract][Full Text] [Related]
18. Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
Front Immunol; 2019; 10():1856. PubMed ID: 31440245
[TBL] [Abstract][Full Text] [Related]
19. RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines.
Shen L; Zhang J; Lee H; Batista MT; Johnston SA
Sci Rep; 2019 Oct; 9(1):14184. PubMed ID: 31578439
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of mRNA therapies against solid tumors.
Wu D; Hu L; Wang X; Yu Y; Jia SP; Huang HY; Li ZW; Ma JF; Zhu HB; Tang Y; Li N
J Hematol Oncol; 2023 Jul; 16(1):75. PubMed ID: 37464375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
